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Xenobiotic transporters play key roles in disposition of a certain therapeutic agents 
although limited information is available on their roles other than pharmacokinetic 
issues. Here, suppressive effect of multispecific organic cation transporter 
OCTN1/SLC22A4 on liver fibrosis was proposed in liver injury models. After injection 
of hepatotoxins such as dimethylnitrosamine (DMN) or concanavalin A, hepatic fibrosis 
and oxidative stress, evaluated in terms of Sirius red and 4-hydroxy-2-nonenal staining, 
respectively, were more severe in liver of octn1/slc22a4 gene knockout (octn1-/-) mice 
than that in wild-type mice. DMN treatment markedly increased α-smooth muscle actin 
(α-SMA) and F4/80, markers of activated stellate and Kupffer cells, respectively, in 
liver of octn1-/-, but had less effect in wild-type mice. Thus, octn1/slc22a4 gene deletion 
results in more sever hepatic fibrosis, oxidative stress and inflammation. DMN-treated 
wild-type mice showed increased Octn1 staining and hepatic concentration of its 
food-derived antioxidant ergothioneine. The up-regulated Octn1 was colocalized with 
α-SMA. Functional expression of Octn1 was demonstrated in activated human hepatic 
stellate cell lines, LI90 and LX-2. Provision of ERGO-rich feed ameliorated 
DMN-induced liver fibrosis and oxidative stress. Overall, Octn1 is up-regulated in 
activated stellate cells, resulting in increased delivery of its substrate antioxidant 
ergothioneine, and has protective effect against liver fibrosis. 
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Introduction 
     Liver fibrosis is a complex process that includes apoptosis of hepatocytes, 
infiltration of inflammatory cells, induction of inflammatory cytokines and proliferation 
of extracellular-matrix (ECM)-producing nonparenchymal cells (NPCs) [1, 2]. The 
resultant enhancement of ECM production can disrupt the balance between synthesis 
and degradation of ECM, progressively worsening the fibrosis. Liver fibrosis can 
silently progress, leading to liver cirrhosis and hepatocellular carcinoma, and is 
observed in various chronic hepatic diseases that develop following inflammatory 
stimuli such as viral infection, alcohol, drugs and non-alcoholic steatohepatitis (NASH) 
[3, 4]. Notwithstanding the pivotal role of fibrosis in hepatic diseases, few therapeutic 
agents that can directly suppress hepatic fibrosis are available.  
     Solute carrier SLC22A4 was first identified as carnitine/organic cation transporter 
1 (OCTN1) in human fetal liver, but is expressed ubiquitously in organs [5, 6]. 
OCTN1/SLC22A4 is multispecific transporter which accepts various types of 
therapeutic agents as substrates [5, 6]. Metabolome analysis using cell lines transfected 
with SLC22A4 gene in vitro and octn1/slc22a4 gene knockout (octn1-/-) mice in vivo 
have demonstrated that OCTN1 most efficiently transports a naturally occurring 
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food-derived antioxidant, ergothioneine (ERGO) [7, 8]. ERGO is highly hydrophilic, 
and its uptake through plasma membranes is primarily mediated by OCTN1, as 
evidenced by the fact that food-derived ERGO is detected at µM to sub-mM level in 
almost all organs in wild-type mice, but minimally detected in octn1-/- mice [8]. After 
oral ingestion, ERGO is efficiently absorbed in the gastrointestinal tract by OCTN1, 
then almost completely taken up by the liver and apparently not metabolized in the body 
[8, 9]. Thus, ERGO is mainly delivered to the liver after oral ingestion. Interestingly, 
ERGO is minimally taken up into liver parenchymal cells, but selectively taken up into 
NPCs [9]. This is consistent with the minimal immunoreactivity of hepatocytes with 
OCTN1 antibody [9]. Thus, OCTN1 could be unique drug transporter expressed in 
NPCs in the liver. 
     Hepatic NPCs contribute to production and secretion of multiple cytokines and 
inflammation-related substances, and are constantly exposed to oxidative stress [10, 11]. 
In particular, hepatic stellate cells (HSCs) are activated by oxidative stress to 
collagen-producing myofibroblasts, which promote liver fibrosis by producing ECM 
[12, 13]. Oxidative stress may also injure parenchymal cells, leading to further 
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progression of liver injury. It was recently reported that antioxidant and 
radical-scavenging enzymes can ameliorate hepatic fibrosis and injuries [14, 15]. Thus, 
proper control of the oxidative stress-antioxidant balance may inhibit the onset and/or 
progression of hepatic fibrosis. 
     Because ERGO is a stable antioxidant that can directly scavenge reactive oxygen 
species (ROS) [16, 17], it may have a protective role against oxidative stress after its 
uptake into NPCs. Nevertheless, pathophysiological role of ERGO and its transporter 
OCTN1 is minimally understood. Information on localization and function of the drug 
transporter in disease-related cells like NPCs may give an insight in novel drug delivery 
and pharmacotherapeutics. The purpose of the present study is to test the hypothesis that 
OCTN1 plays a role in suppression of oxidative stress and hepatic fibrosis by mediating 
delivery of its food-derived antioxidant substrate ERGO into hepatic NPCs. To examine 
this hypothesis, hepatic fibrosis models were constructed by two different hepatotoxins, 
dimethylnitrosamine (DMN) and concanavalin A (ConA) in wild-type and octn1-/- mice. 
DMN is widely used to produce model of hepatic fibrosis since the model can 
reproduce most of the features of human hepatic fibrosis [18, 19, 20]. On the other hand, 
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immunological responses are involved in pathogenesis of hepatic fibrosis in human, and 
administration of ConA leads to activation of immune system, resulting in hepatic 
fibrosis, which reproduces one of major pathology in human [21, 22]. NASH model was 
also constructed to evaluate OCTN1 expression during chronic liver injury. 
 
Materials and methods 
Materials 
 DMN and ConA were purchased from Wako Pure Chemical Industries (Osaka, 
Japan) and Sigma-Aldrich, Inc. (St. Louis, MO), respectively. 
N-Morpholinosydnonimine hydrochloride (SIN-1) was purchased from Dojindo 
Laboratories (Kumamoto, Japan). Mouse monoclonal antibodies against human 
α-smooth muscle actin (α-SMA) and 4-hydroxy-2-nonenal (4HNE), and rat monoclonal 
antibodies against F4/80 were obtained from Dako North America Inc. (Carpinteria, 
CA), Wako Pure Chemical Industries and Abcam Inc. (Cambridge, MA), respectively. 
[3H]Ergothioneine ([3H]ERGO; 293 Ci/mol) was purchased from Moravek 
Biochemicals (Brea, CA), diluted with transport buffer and stored at -30 ˚C. Its quality 
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was verified by checking the difference in the uptake between HEK293 cells stably 
transfected with SLC22A4 gene and vector alone. Deuterium-labeled L-ergothioneine 
(ERGO-d9) was obtained from Tetrahedron (Vincennes, France). All other chemicals 
were commercial products of analytical grade. 
 
Animals 
 Mice were used for all experiments at 6-8 weeks of age. The octn1-/- mice [8] 
and littermates were of a mixed genetic background (C57BL/6J and 129Sv/Ev), 
produced by intercrossing octn1+/- mice. They had free access to food (Sankyo-labo, 
Toyama, Japan), which contained approximately 0.2 µg ERGO/g chaw and water, 
except during the oral administration study of ERGO-rich feed. The present study was 
carried out in accordance with the Guide for the Care and Use of Laboratory Animals in 
Kanazawa University. 
 
Models of Liver Fibrosis  
 Liver fibrosis was induced in female mice by intraperitoneal administration of 
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DMN at 10 µg/g body weight (1% w/v dissolved in saline solution) for the first three 
consecutive days of the week under light ether anesthesia as described previously [23]. 
The ConA-induced hepatitis model was constructed in male mice by injection of ConA 
(20 µg/g body weight) dissolved in PBS via the jugular vein once a week for 2 weeks 
[24]. Control mice received an equal volume of vehicle only. To develop NASH model, 
male mice were started at 7 weeks of age on an atherogenic high-fat diet (HFD) 
composed of cocoa butter, cholesterol, cholate, and corticotropin-releasing factor-1 
(Oriental Yeast Co., Tokyo, Japan) for 14, 24 or 36 weeks. 
 
Oral Administration of ERGO-rich Feed  
 Powdered extract of golden oyster mushroom containing 1% w/w ERGO 
(aminothioneine®, L•S Corporation, Tokyo) and ERGO-free feed (basal diet®, TestDiet, 
St. Louis, MO) which contains less than 0.01 µg ERGO/g chaw according to our 
LC-MS/MS determination. These were mixed in the ratio of 95:5 to prepare ERGO-rich 
diet containing 0.05% w/w of ERGO. C57BL/6J female mice were fed with ERGO-free 
or ERGO-rich diet for 8 weeks, and DMN treatment was performed in the final week. 
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Mice were then sacrificed, and liver was excised. 
 
Histology and Immunohistochemistry 
 The liver samples were harvested from mice and immersion-fixed overnight in 
PBS containing 4% paraformaldehyde (PFA). The fixed liver was sequentially 
cryoprotected in 10, 20 and 30% sucrose in PBS, embedded in optimal cutting 
temperature compound and frozen at -30°C. Free-floating sections were cut at 10 µm 
using a Leica cryostat. Tissue sections were stained with picro-Sirius Red solution 
(0.1% Direct Red 80 dissolved in saturated picric acid) to visualize collagen deposition. 
The staining signals were visualized using a BIOREVO BZ-9000 microscope (Keyence, 
Osaka, Japan) and quantified using Dynamic cell count BZ-H1C software (Keyence). 
For quantification, the number of pixels showing the red color of stained collagen fibers 
was extracted after establishing a color threshold, and the percentage of those fibers in 
the liver was calculated by dividing the total red-colored area by the total area of the 
liver. Frozen sections were also heated at 92 ˚C for 15 min in 20 mM Tris buffer (pH 
9.0) for antigen activation. Following successive pretreatments with 0.3% Tween 
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20/PBS for 20 min, 0.3% H2O2/PBS for 30 min and blocking solution (1% BSA, 5% 
skim milk and 1.5% goat serum in PBS) for 30 min, the sections were incubated 
overnight with anti-OCTN1, anti-α-SMA, anti-F4/80 or 4HNE antibody at 4˚C, 
followed by washing with PBS and further incubation with biotinylated anti-rabbit IgG, 
anti-mouse IgG or anti-rat IgG, repectively (Vector Laboratories, Burlingame, CA), for 
1 h at room temperature. The immunoreaction product was visualized by incubating the 
sections successively with VECTASTAIN Elite ABC Standard Kit (Vector Laboratories) 
for 30 min and Peroxidase Substrate Kit including 3’,3’-diaminobenzidine 
tetrahydrochloride (ImmPACT DAB, Vector Laboratories, Burlingame, CA) for 
approximately 10 sec. Finally, the specimens were mounted in VECTASHIELD 
mounting medium (Vector Laboratories), and examined with a BIOREVO BZ-9000 
microscope. 
 
Flow Cytometry of Isolated NPCs 
Hepatic NPCs were isolated from two mice for each group as described 
previously [8], then fixed and permeabilized with kit reagents (BD Biosciences), and 
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stained with anti-OCTN1 and α-SMA antibodies for 30 min at room temperature. Cells 
were then washed with Perm/Wash Buffer (BD Biosciences) and incubated with 
secondary antibodies for 30 min at room temperature. Cells were further washed with 
Perm/Wash Buffer, and analyzed on a FACSCalibur flow cytometer (BD Biosciences).  
 
Quantification of Malondialdehyde (MDA) and ERGO in mice organs 
 MDA concentration in the liver was determined using the TBARS Assay Kit 
(Cayman Chemical, Ann Arbor, MI) according to the manufacturer's recommendations. 
ERGO concentrations in blood, liver and kidney were determined using HPLC [8].  
 
Cell Culture 
 LI90, human hepatic stellate cells, were obtained from Japanese Collection of 
Research Bioresources (Osaka, Japan) and grown in Dulbecco’s modified Eagle’s 
medium (Sigma-Aldrich) supplemented with 10% FBS, 1% sodium pyruvate, 100 
unit/mL benzylpenicillin and 0.14 mg/mL streptomycin in a humidified atmosphere of 
5% CO2 in air at 37˚C. LI90 cells were activated with peroxynitrite donor SIN-1 (0.1 
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mM) for 24 hr in serum-free DMEM according to previous report [25]. For knockdown 
of OCTN1 with small interfering RNA (siRNA), cells were transiently transfected with 
siRNA (BONAC Corporation, Kurume, Japan) for OCTN1 by lipofectamine 
RNAiMAX (Invitrogen, Carlsbad, CA) in Opti-MEM according to the manufacturer’s 
instructions. Culture medium was replaced with DMEM supplemented with 10% FBS 
at 24 h after the transfection, followed by further culture for 48 hr. Another human 
hepatic stellate cell line, LX-2 was purchased from Merck Millipore Japan (Tokyo, 
Japan). Cells were grown in Dulbecco’s modified Eagle’s medium (Sigma-Aldrich) 
supplemented with 10% FBS, 100 unit/mL benzylpenicillin and 0.14 mg/mL 
streptomycin in a humidified atmosphere of 5% CO2 in air at 37˚C. LX-2 cells were 
activated by treatment with 10 ng/mL TGF-β in 1% FBS DMEM for 24 hours according 
to previous report [26, 27].  
 
Immunocytochemistry 
 Cells were grown on cover glass (12 mm ; thickness, 0.12-0.17 mm; 
Matsunami Glass Inc., Osaka, Japan) and fixed with 3% formaldehyde in PBS, 
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permeabilized with methanol for 5 min and incubated with PBS containing 3% skim 
milk and 5% goat serum for 30 min at room temperature. Cells were then incubated 
overnight with anti-OCTN1 and anti-α-SMA antibodies at 4˚C. Cells were washed with 
PBS and further incubated with Alexa Fluor 488 goat anti-rabbit IgG and Alexa Fluor 
594 goat anti-mouse IgG (Molecular Probes Inc., Eugene, OR) for 30 min at room 
temperature. Attached cells were sealed onto the slides using Vectrashield mounting 




 LI90 cells grown on collagen-coated 6-well plates were washed with the 
transport buffer and incubated with [3H]ERGO (7.9 µM) for 60 min [9]. The cells were 
washed three times with ice-cold buffer and dried at room temperature, followed by 
addition of 0.2 M NaOH. For determination of radioactivity, the solubilized sample was 
neutralized with 5 M HCl, and the associated radioactivity was measured with a liquid 
scintillation counter, LSC-5100 (Aloka, Tokyo, Japan) with Clearsol I (Nacalai Tesque, 
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Inc., Kyoto, Japan) as the scintillation fluid. LX-2 cells were grown on poly-L-lysine 
coated 12-well plates, washed with the transport buffer and incubated with ERGO-d9 
(10 µM) for 120 min. A mixture of ERGO-d9 (10 µM) and unlabeled ERGO (0-300 
µM) was incubated for 120 min for kinetic analysis. The cells were washed three times 
with ice-cold buffer, dried at room temperature and burst with distilled water. ERGO-d9 
was quantified by LC-MS/MS. Uptake was normalized both by cellular protein and 
medium concentration, and represented as distribution volume (µL/mg protein). 
 
LC-MS/MS analysis 
Quantification of d9-ERGO was performed using a triple quadruple mass 
spectrometer with electrospray ionization (ESI) coupled to a liquid chromatography 
system (LCMS-8040; Shimadzu, Kyoto, Japan). Chromatography was performed by 
means of a step-gradient elution (flow rate, 0.4 ml/min) as follows: 0–0.5 min, 5% 
A/95% B; 0.5–2.0 min, 5% A/95% B to 25% A/75% B; 2.0–3.0 min, 25% A/75% B to 
70% A/30% B; 3.0–4.0 min, 70% A/30% B; 4.0–4.1 min, 70% A/30% B to 5% A/95% 
B; 4.1-6.5 min, 5% A/95% B (A, water containing 0.1% formic acid; B, acetonitrile 
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containing 0.1% formic acid) using an SeQuant® ZIC®-cHILIC Column (100 Å, 3 μm, 
2.1 mm × 150 mm; Merck) at 40 °C. MS–MS detection was performed in positive 
electrospray ionisation mode using multiple reaction monitoring (MRM) acquisition 
mode. The MRM was set at 239.15 to 127.00 m/z for d9–ERGO, 253.10 to 159.10 for 
cimetidine (internal standard). 
 
Quantitative RT-PCR 
Tissue samples were immediately transferred to RNAlater (Sigma-Aldrich, St. 
Louis, MO) and incubated at 4°C overnight, followed by preservation at -30°C until 
RNA extraction. Total RNA was extracted according to the standard ISOGEN procedure 
(Nippon Gene, Toyama, Japan) and used for cDNA synthesis with oligo (dT)12-18 primer, 
deoxy nucleotide triphosphate mix, RT buffer and MultiScribe™ reverse transcriptase 
(Applied Biosystems, Foster City, CA). The individual cDNA species were amplified in 
a reaction mixture containing a cDNA aliquot, relevant sense and antisense primers as 
shown in supplementary table 1, and THUNDERBIRD SYBR qPCR Mix (TOYOBO, 
Osaka, Japan). An Mx3005P real-time PCR apparatus (Agilent Technologies, Santa 
  17 
Clara, CA) was employed. PCR reactions were initiated by template denaturation at 
95 °C for 15 min, followed by 40 cycles of amplification (denaturation at 95°C for 10 s, 




 The results were expressed as mean ± SEM. The statistical significance of 
differences was determined by means of Student’s t-test or one-way ANOVA with the 
Bonferroni/Dunn test, and p < 0.05 was regarded as denoting a significant difference.  
 
Results 
Marked fibrosis and oxidative stress in liver of octn1-/- mice after treatment with DMN 
or ConA 
Hepatic fibrosis models were constructed in both wild-type and octn1-/- mice 
by injection of DMN or ConA in order to clarify the possible role of Octn1 in liver 
fibrosis. The degree of fibrosis and oxidative stress were assessed in liver sections in 
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terms of Sirius red staining and 4HNE staining, respectively. At one week after DMN 
treatment, marked Sirius red staining was observed in octn1-/-, while weaker staining 
was observed in wild-type mice (Fig. 1A, 1B). 4HNE staining was also marked in 
octn1-/-, but weaker in wild-type mice (Fig. 1C, 1D). The effect of Octn1 on fibrosis and 
oxidative stress was also examined in another fibrosis model prepared with ConA. At 
two weeks after ConA treatment, both Sirius red and 4HNE staining was more marked 
in octn1-/- than in wild-type mice (Fig. 1E, 1F, 1G, 1H). In both experiments, vehicle 
controls showed minimal staining (Fig. 1). To confirm that oxidative stress is higher in 
octn1-/- mice, gene expression of oxidative stress markers, superoxide dismutase (SOD) 
1 and NADPH oxidase (NOX) 4, was examined. Expression of both genes at 1 week 
after DMN treatment was higher in octn1-/- than in wild-type mice (Table 1). 
To further characterize the difference in liver fibrosis between wild-type and 
octn1-/- mice, activated HSC and Kupffer cells were identified by staining with 
anti-α-SMA and F4/80 antibodies, respectively. At 1 week after DMN treatment, gene 
expression of α-SMA tended to be higher in octn1-/- than in wild-type mice, although 
this difference was not statistically significant (Table 1). On the other hand, at 3 weeks 
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after DMN treatment, both α-SMA and F4/80 were detected and were more strongly 
stained in liver of octn1-/- than wild-type mice (Fig. 2B, 2C). At 3 weeks after DMN 
treatment, Sirius red staining was more intense in octn1-/- than in wild-type mice (Fig. 
2A), though the difference was not large. Sirius red staining was marked in both 
wild-type and octn1-/- mice at 4 and 5 weeks after DMN treatment, and at 4 weeks after 
ConA treatment, but the difference between the two strains was minimal at these time 
points (data not shown). Oxidative stress, assessed as MDA, tended to be increased in 
the liver of octn1-/- mice (Fig. 2D). 
 
Up-regulation of OCTN1 in activated HSC 
Since Octn1 accepts ERGO as a substrate, the higher oxidative stress in 
octn1-/- may be compatible with the lower ERGO concentration in these mice. 
Food-derived ERGO in the liver was measured; it was detected in wild-type mice, but 
was under the detection limit in octn1-/- (Fig. 3D). Interestingly, ERGO concentration in 
the liver, but not kidney, after DMN treatment of wild-type mice was significantly 
higher than that in the wild-type control (Fig. 3D). Therefore, immunostaining with 
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Octn1 antiserum [9] was performed using sequential liver slices at three weeks after 
DMN treatment. Octn1 staining was increased after DMN treatment, compared with the 
control (Fig. 3A). The Octn1 staining in control mice was minimally detected in the 
present immunostaining condition (Fig. 3A). The signal pattern of Octn1 in 
DMN-treated mice resembled that of α-SMA, rather than F4/80 (Fig. 3B). Nonspecific 
binding of the Octn1 antiserum was checked by comparing signals in the liver sections 
of wild-type and octn1-/- mice. Although weak nonspecific signal was observed in 
octn1-/- mice, the signal was much more obvious in wild-type mice. To examine the 
localization of Octn1 in activated HSC, we performed flow-cytometric analysis using 
anti-OCTN1 antibody. The population of NPCs positive for both Octn1 and α-SMA 
after DMN treatment was higher than that in the control (50.2 vs 30.7%, Fig. 3C), 
suggesting up-regulation of OCTN1 in activated HSCs.  
 
OCTN1 is functionally expressed in human hepatic stellate cell lines LI90 and LX-2 
To further support the localization of OCTN1 in activated HSCs, functional 
expression of OCTN1 in LI90 was assessed in terms of uptake of [3H]ERGO. The 
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uptake was time-dependent and reduced in the presence of an excess of unlabeled 
ERGO (Fig. 4A). Next, we investigated the effect of knockdown of OCTN1 on the 
expression and function of OCTN1 in LI90. After OCTN1 siRNA (siOCTN1) treatment, 
gene expression of OCTN1 was almost completely blocked with a concomitant 
reduction in [3H]ERGO uptake, compared with the situation after treatment with control 
siRNA (siControl, Fig. 4B). Immunocytochemical analysis confirmed the expression of 
α-SMA (Fig. 4C, bottom) and OCTN1 (Fig. 4C, top) in LI90. HSCs are known to be 
activated by fibrosis-related cytokines such as tumor necrosis factor (TNF)-α and 
transforming growth factor (TGF)-β. Thus, we examined the effect of these cytokines 
on the expression and function of OCTN1 in LI90 cells. TNF-α significantly increased 
gene expression of SLC22A4 in LI90 cells whereas TGF-β minimally showed such 
effect (Fig. 4D). Uptake of [3H]ERGO in LI90 cells was also increased by treatment 
with TNF-α, but not TGF-β (Fig. 4E). To further investigate whether OCTN1 is 
functionally expressed in HSCs, another human HSC line LX-2 was used. ERGO-d9 
was taken up into LX-2 cells in time-dependent manner (Fig. 4F, top). Concentration 
dependent uptake of ERGO was also examined, yielding Km and Vmax values of 194 
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µM and 90.7 pmol/mg protein/min, respectively (Fig. 4F, bottom). Expression of 
OCTN1 gene product was also confirmed in LX-2 cells according to 
immunocytochemical analysis (Fig. 4G). Direct effect of ERGO on oxidative stress 
markers was also evaluated in LI90 cells. Gene expression of NOX4 in LI90 was 
significantly reduced by treatment with ERGO whereas that of α-SMA tended to be 
reduced with ERGO (Fig. 4H). 
 
Oral intake of ERGO-rich feed suppressed oxidative stress and liver fibrosis 
The up-regulation of Octn1 during liver fibrosis (Figs. 3) would be consistent 
with an ameliorative effect of orally administered antioxidant ERGO, which would be 
delivered to activated HSCs via Octn1. To investigate the effect of ERGO in vivo, mice 
were given an ERGO-rich diet. Liver fibrosis was induced by DMN at 7 weeks after the 
start of this diet, and then Sirius red staining and immunostaining of 4HNE were 
examined. Ingestion of the ERGO-rich diet decreased Sirius red staining, compared 
with normal diet (Fig. 5A). Quantification revealed significantly weaker Sirius red 
staining after the ERGO-rich diet than after the control diet (Fig. 5B). 4HNE staining 
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was also reduced, compared with that in mice given the control diet (Fig. 5C, 5D). To 
support the pharmacological effect of ERGO, its concentrations in blood and liver were 
measured in the same experiments. ERGO concentration in blood of mice fed the 
ERGO-rich diet gradually increased, and at the end of the experiment, ERGO 
concentration in blood and liver was more than 50-fold higher than in the control group 
(Fig. 5E).  
 
Up-regulation of Octn1 in the liver of NASH model mice 
 To further understand the pathological relevance of Octn1, we constructed 
HFD-induced NASH model mice. Sirius red staining was markedly elevated in the liver 
at 14, 24 and 36 weeks after the start of HFD treatment, compared with the control (Fig. 
6A). Immunostaining of Octn1 in the liver was also obvious (Fig. 6B).  
 
Discussion 
 Here, we proposed a protective role of xenobiotic transporter Octn1 in two 
independent hepatic fibrosis models in mice: Sirius red staining in the liver of octn1-/- 
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was greater than that in wild-type mice at 1 and 2 weeks after treatment with DMN (Fig. 
1A, 1B) and ConA (Fig. 1E, 1F), respectively, indicating a higher degree of hepatic 
fibrosis in octn1-/-. The protective role of Octn1 against liver fibrosis was further 
supported by the stronger staining of α-SMA (Fig. 2B) and F4/80 (Fig. 2C), which 
represent activated HSC and Kupffer cells, respectively, in liver of octn1-/-, compared 
with wild-type mice, at 3 weeks after DMN treatment. At this time, hepatic fibrosis was 
severe in octn1-/-, but was also present in wild-type mice (Fig. 2A). Thus, OCTN1 may 
influence the early stage (~1 week after DMN treatment) of liver fibrosis. Association 
of Octn1 with hepatic fibrosis was further confirmed by the up-regulation of this 
transporter in the liver after DMN treatment (Fig. 3A, 3C). The increase in Octn1 gene 
product with increase in fibrosis stage was also observed in HFD-induced NASH model 
mice (Fig. 5A, 5B). Up-regulation of Octn1 is consistent with the increase in hepatic 
concentration of food-derived Octn1 substrate ERGO in the liver after DMN treatment 
in wild-type mice (Fig. 3D).  
Hepatic fibrosis is known to primarily occur via activation of HSCs, which 
produce ECMs such as collagen. Therefore, we next examined possible localization of 
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OCTN1 in HSCs. Immunostaining of Octn1 resembled that of α-SMA, but not F4/80, in 
liver sections (Fig. 3B). Colocalization of Octn1 with α-SMA was confirmed in 
flow-cytometric analysis of hepatic NPCs isolated from the liver of DMN-treated mice 
(Fig. 3C). OCTN1 was also colocalized with α-SMA in two different activated human 
HSC lines, LI90 and LX-2 (Fig.4C, 4G). Functional expression of OCTN1 in HSCs was 
supported by the observation of time-dependent uptake of [3H]ERGO and ERGO-d9 in 
LI90 and LX-2 cells, respectively (Fig. 4A, 4F), and its decrease in response to 
siOCTN1 treatment (Fig. 4B). Thus, OCTN1 is possibly localized in HSCs, and the 
increase in the population of Octn1/α-SMA double-positive cells after DMN treatment 
(Fig. 3C) indicates that Octn1 is up-regulated in activated HSCs. These results support 
the protective role of OCTN1 in experimental fibrosis (Figs. 1 and 2) possibly linked to 
the functional expression and up-regulation of this transporter in activated HSCs. 
The progression of liver fibrosis is promoted by oxidative stress [12, 13], 
although this is likely to be just one of multiple processes involved. In the present study, 
oxidative stress in the liver of octn1-/- was much greater than that in wild-type mice at 1 
and 2 weeks after treatment with DMN (Fig. 1C, 1D) and ConA (Fig. 1G, 1H), 
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respectively, supporting the association of oxidative stress with progression of fibrosis. 
The increased level of oxidative stress in octn1-/- may suggest that OCTN1 plays a 
protective role against oxidative stress. OCTN1 has been characterized as a unique 
transporter expressed in NPCs [9] and transporting the food-derived antioxidant ERGO 
[7, 8]. The major source of ERGO is fungi and mycobacteria, and endogenous 
biosynthesis is minimal in mammals [16, 17]. Hepatic extraction of ERGO is almost 
complete, meaning that essentially all orally absorbed ERGO is taken up by the liver [9]. 
Therefore, OCTN1-mediated uptake of ERGO in hepatic NPCs may explain the 
protective role of OCTN1 in HSCs against oxidative stress. Actually, food-derived 
ERGO was detected in the liver of wild-type mice, but not in octn1-/- mice (Fig. 3D), 
which exhibited more severe 4HNE staining (Fig. 1). Additionally, orally administered 
ERGO-rich feed exerted anti-fibrotic effect in DMN-treated mice (Fig. 5). OCTN1 is 
multispecific transporter which accepts various types of organic cations as substrates. 
Therefore, OCTN1-mediated ERGO uptake and anti-fibrotic effect may imply that 
OCTN1 is a novel target to deliver therapeutic agents into HSCs, thereby protecting 
hepatic fibrosis. Hepatic fibrosis is a progressive disease, leading to cirrhosis and liver 
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cancer. Elevation of hepatic enzyme activities in serum is not obvious in relatively mild 
chronic liver injury, and therefore, establishment of techniques for early diagnosis of 
liver fibrosis is also required. Measurements of OCTN1 and/or its substrates may be 
available for early diagnosis of liver fibrosis. In addition, since ERGO-rich diet 
ameliorated liver fibrosis (Fig. 5), ERGO may have value as a protective agent against 
liver fibrosis. 
It should be noted that ERGO is included in normal diets and is therefore 
usually present at a substantial concentration in the liver under the normal diet condition 
(Fig. 3D). This may hinder direct demonstration of the amelioration of liver fibrosis by 
ERGO in vivo. In order to examine the anti-fibrosis effect of exogenously administered 
ERGO, therefore, we screened several brands of mouse chaw to find an ERGO-free diet 
in the present study. Indeed, mice in the control group given this ERGO-free diet 
showed a decrease of ERGO concentration in blood from 13.7±0.5 at the start of the 
experiment to 1.34±0.14 µg/mL at 8 weeks on the ERGO-free diet. At this time point, 
mice on the ERGO-rich diet showed a blood ERGO concentration of 183±3 µg/mL 
(Fig. 5E). This large difference in exposure to ERGO supports the idea that the 
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anti-fibrosis and oxidative stress effects (Fig. 5A-5D) resulted at least partially from 
ingestion of ERGO, although we cannot rule out possible effects of other components 
included in the ERGO-rich diet due to the supplementation with mushroom extract. It 
has been reported that mushroom extract suppresses hepatic fibrosis [28, 29], but little is 
known about the mechanism. Considering that ERGO is present at high levels in fungi 
and mushrooms [16, 17], the beneficial effect of mushroom extract could be largely due 
to ERGO. 
Gene expression of SLC22A4 is induced by treatment with TNF-α, but not 
other inflammatory cytokines such as interleukin (IL)-1β, 6 and interferon-γ in human 
intestinal epithelial cells Caco-2 [30], whereas both TNF-α and IL-1β induce SLC22A4 
gene expression in human fibroblast-like synoviocyte cell line MH7A [31]. In the 
present study using LI90, both OCTN1 mRNA and [3H]ERGO uptake were 
significantly increased by TNF-α, but not TGF-β (Fig. 4D, 4E). TNF-α is a key 
mediator in hepatic fibrosis [33] and, therefore, may serve as a trigger to induce 
SLC22A4 gene expression during liver fibrosis, leading to up-regulation of SLC22A4 
gene product in activated HSCs. On the other hand, TGF-ß is also an important cytokine 
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for inducing collagen production in hepatic fibrosis [33]. Therefore, TGF-ß may not be 
directly associated with the up-regulation of OCTN1, but may play a distinct role in 
liver fibrosis. 
ERGO exerts its antioxidant activity at sub-mM to mM concentrations [34-36], 
whereas the hepatic ERGO concentration in control and DMN-treated mice was at most 
100~200 µM (Fig. 3D). However, considering that OCTN1 is almost exclusively 
expressed in HSCs (Fig. 3B) and HSCs comprise only a minor population among total 
hepatic cells, it is plausible that the ERGO concentration in HSCs could be at mM level. 
Nevertheless, it is not clear whether loss of the antioxidant effect of ERGO alone can 
explain the higher liver fibrosis and higher oxidative stress found in octn1-/- mice. We 
should consider the possibility of other protective effect(s) exerted by ERGO on liver 
fibrosis. For example, NADPH oxidase (NOX) is an important source of ROS, which 
could be involved in progression of liver fibrosis [37-39]. NOX4, an isoform of NOX, 
is highly expressed in hepatocytes and HSCs [40]. In the present study, mRNA for 
NOX4 in the liver of octn1-/- was significantly higher than in wild-type mice after DMN 
treatment (Table 1). In addition, gene expression of NOX4 in LI90 was significantly 
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reduced by treatment with ERGO (Fig. 4H). These results may mean that one of the 
candidate target genes for ERGO is NOX4, and down-regulation of this gene may be 
involved in the reduction of oxidative stress and suppression of liver fibrosis. 
In conclusion, OCTN1 plays a protective role in liver fibrosis models. This 
probably results from up-regulation in activated HSCs and increase in uptake of ERGO 
at an early stage of liver fibrosis. OCTN1 may be thus a novel target for the delivery of 
therapeutic agents into activated HSCs. 
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Figure legends 
Fig. 1.  Fibrosis and oxidative stress in liver of wild-type and octn1-/- mice treated 
with DMN and ConA 
Liver sections were obtained 1 and 2 weeks after treatment with DMN (A-D) or ConA 
(E-H), respectively, and stained with Sirius red (A, B, E, F) and anti-4HNE antibody (C, 
D, G, H). The control represents treatment with vehicle alone. Representative results 
from at least three individual mice in each group are shown (A, C, E, G). The 
histochemical staining was subjected to image analysis, and the area occupied by the 
signal was quantified and shown (B, D, F, H, mean±SEM, n=3). *Significantly different 
from wild-type mice treated with DMN (p<0.05). 
 
Fig. 2   Activation of hepatic stellate and Kupffer cells in the liver of wild-type 
and octn1-/- mice after DMN treatment 
Liver tissues were obtained from wild-type and octn1-/- mice 3 weeks after treatment 
with DMN. The liver sections were then stained with Sirius red (A), and anti-α-SMA 
(B) and anti-F4/80 (C) antibodies. Representative results from at least three individual 
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mice in each group are shown. (D) Concentration of MDA in liver was determined 
(mean±SEM, n=4-8). The control represents treatment with vehicle alone.  
 
Fig. 3  Localization of OCTN1 in activated stellate cells and its up-regulation 
after DMN treatment. 
(A) Liver sections were obtained from wild-type mice at 3 weeks after treatment with 
DMN or vehicle alone (Control), and stained with anti-OCTN1 antibody. 
Representative results from seven DMN-treated and five control mice are shown. (B) 
Serial slice sections were obtained from wild-type mice at 3 weeks after DMN treatment 
and immunostained with anti-OCTN1, α-SMA and F4/80 antibodies (OCTN1-positive 
areas are surrounded by circles). (C) Isolated hepatic NPCs were incubated with 
anti-OCTN1 and α-SMA antibodies, and analyzed by flow cytometry to quantify the 
population of OCTN1 and α-SMA double-positive cells to total NPCs (%). The whole 
experiment was repeated three times, and typical data are shown. (D) Concentration of 
ERGO in liver and kidney was determined (mean±SEM, n=4-8). *Significantly 
different from the control (p<0.05). N.D., under the detection limit (< 1.5 µg/g tissue). 
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Fig. 4  Functional expression of OCTN1 in LI90 (A-E, H) and LX-2 (F, G). 
(A) Uptake of [3H]ERGO was measured in LI90 cells in the absence (◯) or presence 
(●) of 200 µM unlabeled ERGO. The experiment was repeated three times, and typical 
data representing mean±SEM of three wells are shown. (B) Gene expression of OCTN1 
and uptake of [3H]ERGO were measured after transfection of siRNA for OCTN1. Data 
represent mean±SEM of three wells. (C) Immunocytochemical analysis was performed 
for both OCTN1 and α-SMA. The experiment was repeated three times, and typical 
results are shown. (D, E) Gene expression of SLC22A4 (D) and uptake of [3H]ERGO 
(E) were measured after treatment with TNF-α (10 ng/mL) or TGF-ß (1 ng/mL) for 48 
hr. Data represent mean±SEM of three wells. *Significantly different from control (p < 
0.05). (F) Time- and concentration-dependent uptake of ERGO was measured in LX-2 
cells. The experiment was repeated twice, and the data represent mean±SEM of three 
wells. (G) LX-2 cells were activated with TGF-β (10ng/mL) for 24 hr, and both OCTN1 
and α-SMA were immunostained. The experiment was repeated three times, and typical 
results are shown. (H) Gene expression of NOX4 and α-SMA was examined at 48 hours 
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after treatment with 0 or 200 µM ERGO in LI90 cells. Data represent mean±SEM of 
three wells. 
 
Fig. 5  Protective effect of ERGO-rich feed against liver fibrosis and oxidative 
stress. 
Wild-type mice were fed ERGO-free (ERGO(-)) or ERGO-rich (ERGO(+)) diet for 8 
weeks, and treated with DMN or vehicle (control) for the last one week. Liver sections 
were stained with Sirius red (A) and anti-4HNE antibody (C), and quantitative values 
are shown in panels B and D, respectively. Each value represents the mean ± SEM of 4 
to 6 mice in a single experiment. *Significantly different from control mice fed 
ERGO-free diet. #Significantly different from DMN-treated mice fed ERGO-free diet. 
Panel E shows the ERGO concentration in blood and liver (mean±SEM, n=10~12). 
 
Fig. 6  Histochemical staining of liver sections obtained from NASH model mice.  
Liver sections were obtained from mice fed either a normal diet (control) or HFD, and 
stained with Sirius red (A) or anti-OCTN1 antibody (B). 3 mice for each group were 
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used in the experiment. 
